ReviewBlood2008
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.
Review in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 3 syntheses or guidelines pooled it, 376 citations in OpenAlex.
- Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2022Pooled it
- The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens.BMC cancer · 2021Pooled it
- Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis.BMC medicine · 2011Pooled it
- Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age.Leukemia · 2021Trial
- Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Trial
- Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.Annals of hematology · 2014Trial
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.The Lancet. Oncology · 2014Trial
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.The New England journal of medicine · 2013Trial
- Factors associated with executive function in children with lymphoma undergoing chemotherapy: A cross-sectional study based on the theory of unpleasant symptoms.Asia-Pacific journal of oncology nursing · 2026Article
- Diagnostic utility of inflammatory markers in formalin-fixed and paraffin-embedded muscle biopsies for idiopathic inflammatory myopathies.Histopathology · 2026Article
- Diversified cell origin of Helicobacter pylori eradication-responsive gastric diffuse large B-cell lymphomas.The Journal of pathology · 2026Article
- Spontaneous T-cell lymphoblastic lymphoma in a young ICR mouse: a case report.Journal of toxicologic pathology · 2025Article
- Peripheral T-cell lymphoma-NOS in children and adolescents: a review from the Children's Oncology Group NHL Committee.Blood advances · 2025Review
- EBV and post-transplant lymphoproliferative disorder: a complex relationship.Hematology. American Society of Hematology. Education Program · 2024Review
- Molecular Mechanisms of Kaposi Sarcoma-Associated Herpesvirus (HHV8)-Related Lymphomagenesis.Cancers · 2024Review
- Diagnostic and prognostic molecular pathology of lymphoid malignancies.Virchows Archiv : an international journal of pathology · 2024Review
- Major impact of prognosis by age and sex in patients with primary mediastinal large B‑cell lymphoma.Oncology letters · 2024Article
- Feasibility of oral doxycycline as first-line therapy for conjunctival mucosa-associated lymphoid tissue lymphoma.Eye (London, England) · 2024Article
- Artificial Intelligence Applications in Lymphoma Diagnosis and Management: Opportunities, Challenges, and Future Directions.Journal of multidisciplinary healthcare · 2024Review
- Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.Pharmaceutics · 2023Review
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
In the past 50 years, we have witnessed explosive growth in the understanding of normal and neoplastic lymphoid cells. B-cell, T-cell, and natural killer (NK)-cell neoplasms in many respects recapitulate normal stages of lymphoid cell differentiation and function, so that they can be to some extent classified according to the corresponding normal stage. Likewise, the molecular mechanisms involved the pathogenesis of lymphomas and lymphoid leukemias are often based on the physiology of the lymphoid cells, capitalizing on deregulated normal physiology by harnessing the promoters of genes essential for lymphocyte function. The clinical manifestations of lymphomas likewise reflect the normal function of lymphoid cells in vivo. The multiparameter approach to classification adopted by the World Health Organization (WHO) classification has been validated in international studies as being highly reproducible, and enhancing the interpretation of clinical and translational studies. In addition, accurate and precise classification of disease entities facilitates the discovery of the molecular basis of lymphoid neoplasms in the basic science laboratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.